2Q Pharma Results Preview: What Lies Ahead
The big pharma financial reporting season gets underway on July 19 with Novartis and Johnson & Johnson in the vanguard. Biosimilar threats to immunology and cancer drugs and new product ramp-ups are among the key things to watch for as results are announced.
You may also be interested in...
Although Jardiance is supported by outcomes data, it has not yet been incorporated into labeling, nor has it translated into greater sales.
The two big pharmas are working together in oncology in an effort to advance combination therapies in both their growing, but young oncology pipelines.
Boehringer Ingelheim is cutting 724 jobs in the US to "help us reinvent the way we serve the needs of our patients, and enable us to continue to make significant investments in research and development," which aligns with comments earlier this year by the German company's outgoing CEO.